Biotech Values

[exwannabe]

Re: TDLP.OB P3 data

[EDIT: Didn't see DD beat me to this]

[EDIT2: They don't have enough cash to re-run the trial]

"BOOYAAAHH"

Huh?

"Analysis of the Intent-to-Treat (ITT) population of the primary efficacy endpoint (which includes all study patients even if they failed to comply with the protocol and study requirements) favored Ketotransdel® compared to placebo but not to a degree that reached statistical significance. "